These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12161048)

  • 1. Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women.
    Manassiev NA; Godsland IF; Crook D; Proudler AJ; Whitehead MI; Stevenson JC
    Maturitas; 2002 Jul; 42(3):233-42. PubMed ID: 12161048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women.
    Godsland IF; Manassiev NA; Felton CV; Proudler AJ; Crook D; Whitehead MI; Stevenson JC
    Clin Endocrinol (Oxf); 2004 May; 60(5):541-9. PubMed ID: 15104556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion.
    Cucinelli F; Paparella P; Soranna L; Barini A; Cinque B; Mancuso S; Lanzone A
    Eur J Endocrinol; 1999 Mar; 140(3):215-23. PubMed ID: 10216516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up.
    Crook D; Godsland IF; Hull J; Stevenson JC
    Br J Obstet Gynaecol; 1997 Mar; 104(3):298-304. PubMed ID: 9091005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beneficial effects on serum lipoproteins by 17 beta-oestradiol-dydrogesterone therapy in postmenopausal women; a prospective study.
    van der Mooren MJ; Demacker PN; Thomas CM; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1992 Nov; 47(2):153-60. PubMed ID: 1459329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk factors during sequentially combined 17 beta oestradiol and dydrogesterone (Femoston); results from a one-year study in postmenopausal women.
    Gelfand M; Fugère P; Bissonnette F
    Maturitas; 1997 Mar; 26(2):125-32. PubMed ID: 9089562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.
    Kwok S; Charlton-Menys V; Pemberton P; McElduff P; Durrington PN
    Maturitas; 2006 Mar; 53(4):439-46. PubMed ID: 16139447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 2-year study on the beneficial effects of 17 beta-oestradiol-dydrogesterone therapy on serum lipoproteins and Lp(a) in postmenopausal women: no additional unfavourable effects of dydrogesterone.
    van der Mooren MJ; Demacker PN; Thomas CM; Borm GF; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1993 Dec; 52(2):117-23. PubMed ID: 8157140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term influence of different postmenopausal hormone replacement regimens on serum lipids and lipoprotein(a): a randomised study.
    Hänggi W; Lippuner K; Riesen W; Jaeger P; Birkhäuser MH
    Br J Obstet Gynaecol; 1997 Jun; 104(6):708-17. PubMed ID: 9197875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid effects of hormone replacement therapy with sequential transdermal 17-beta-estradiol and oral dydrogesterone.
    Nieto JJ; Cogswell D; Jesinger D; Hardiman P
    Obstet Gynecol; 2000 Jan; 95(1):111-4. PubMed ID: 10636512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
    Schram JH; Boerrigter PJ; The TY
    Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of progestagens on the carotid artery pulsatility index in postmenopausal women on oestrogen replacement therapy.
    Luckas MJ; Gleeve T; Biljan MM; Buckett WM; Aird IA; Drakeley A; Kingsland CR
    Eur J Obstet Gynecol Reprod Biol; 1998 Feb; 76(2):221-4. PubMed ID: 9481579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of oral estradiol and dydrogesterone on carbohydrate metabolism in postmenopausal women.
    Gaspard UJ; Wery OJ; Scheen AJ; Jaminet C; Lefebvre PJ
    Climacteric; 1999 Jun; 2(2):93-100. PubMed ID: 11910673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormone replacement therapy with 17 beta-estradiol dydrogesterone: results of a 3-month open-label study].
    Grisar J; Travica S; Metka M; Pietschmann P
    Wien Klin Wochenschr; 1999 Dec; 111(24):1035-43. PubMed ID: 10677891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study.
    Stojanovic ND; Kwong P; Byrne DJ; Arnold A; Jagroop IA; Nair D; Press M; Hurel S; Mikhailidis DP; Prelevic GM
    Angiology; 2003; 54(4):391-9. PubMed ID: 12934758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of transdermal 17 beta-oestradiol combined with oral progestogen on lipids and lipoproteins in hypercholesterolaemic postmenopausal women.
    Słowińska-Srzednicka J; Zgliczyński S; Chotkowska E; Srzednicki M; Stopińska-Głuszak U; Jeske W; Brzezińska A; Zgliczyński W; Sadowski Z
    J Intern Med; 1993 Nov; 234(5):447-51. PubMed ID: 7693846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women.
    Soranna L; Cucinelli F; Perri C; Muzj G; Giuliani M; Villa P; Lanzone A
    J Endocrinol Invest; 2002 Jun; 25(6):547-50. PubMed ID: 12109627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of body fat distribution by waist circumference, dual-energy X-ray absorptiometry and ultrasonography to insulin resistance by homeostasis model assessment and lipid profile in obese and non-obese postmenopausal women.
    dos Santos RE; Aldrighi JM; Lanz JR; Ferezin PC; Marone MM
    Gynecol Endocrinol; 2005 Nov; 21(5):295-301. PubMed ID: 16373250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women.
    Stevenson JC; Rioux JE; Komer L; Gelfand M
    Climacteric; 2005 Dec; 8(4):352-9. PubMed ID: 16390770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions.
    Farish E; Spowart K; Barnes JF; Fletcher CD; Calder A; Brown A; Hart DM
    Atherosclerosis; 1996 Sep; 126(1):77-84. PubMed ID: 8879436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.